Lenvima 10mg Capsule (Lenvatinib)

Lenvima 10mg Capsule is a targeted therapy-based anticancer medicine. It is used in the treatment of various types of cancer, including differentiated thyroid cancer, liver cancer, kidney cancer, and endometrial cancer. It contains Lenvatinib as an active ingredient that belongs to the tyrosine kinase inhibitor (TKI) class of drugs. It works by blocking the action of a specific protein to stop the growth and multiplication of cancer cells and the formation of new blood vessels. Lenvatinib 10mg capsule is used in differentiated thyroid cancer that is no longer responsive to radioactive iodine therapy and advanced renal cell carcinoma in combination therapy.

The capsule must be taken orally and swallowed whole with water and should not be crushed, chewed, or opened. The prescribed dose and duration of the Lenvatinib 10mg capsule depend on the patient's condition and response to treatment. It can also be taken with or without food. Patients are advised not to change the dosage and timings prescribed by the doctors because it can cause severe side effects.

Common side effects include tiredness, decreased appetite, nausea, vomiting, diarrhea, weight loss, mouth sores, headache, high blood pressure, and changes in thyroid function. A few patients can undergo severe side effects, including severe chest pain, difficulty breathing, severe headache or confusion, significant bleeding, and severe abdominal pain. Most of the Lenvatinib 10mg capsule side effects can leave when the body adapts to the medicine. However, if any side effects persist, inform your doctor immediately.

Women who can become pregnant should use effective contraception during the treatment. Patients must list all medicines, supplements, and herbal products that they are taking. The Lenvatinib 10mg capsule must be used under medical oversight or medical supervision only. Attend regular tests and follow-ups to monitor the medicine response and reduce side effects. Before making any adjustments, changing the dose, or stopping the treatment, consult with your doctor to maximize the benefit.

Kidney, thyroid, endometrial (uterine), and liver cancer

Like any other anticancer medicine, the Lenvima 10mg capsule (lenvatinib) also shows some side effects, which vary from one person to another according to various health factors.

Most of them are mild, and some are serious enough to need immediate medical attention. However, if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately.​

Some common side effects include the following:
● Joint Pain
● Less Hunger
● Weight Loss
● Nausea
● Headache
● Loose And Watery Stools
● Fatigue

The doctor will decide the dose and duration of the Lenvima 10mg capsule (lenvatinib) based on the type & stage of cancer and other factors such as body weight & age. Swallow the whole capsule with a glass of water, as it is an orally available drug.

This capsule can be taken with or without food but at a fixed time every day to get better results. Take it exactly as advised by the doctor; don't miss a dose or overdose on the medicine.

● Fala, L. (2015). Lenvima (lenvatinib), a multireceptor tyrosine kinase inhibitor, approved by the FDA for the treatment of patients with differentiated thyroid cancer. American Health & Drug Benefits, 8(Spec Feature), 176.
● Motzer, R. J., Taylor, M. H., Evans, T. R. J., Okusaka, T., Glen, H., Lubiniecki, G. M., ... & Makker, V. (2022). Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies. Expert review of anticancer therapy, 22(4), 383-400.
● Al-Salama, Z. T., Syed, Y. Y., & Scott, L. J. (2019). Lenvatinib: a review in hepatocellular carcinoma. Drugs, 79(6), 665-674.
● Xu, Z., Wang, Y., Liu, G., Chen, J., Wang, W., Cheng, Y., ... & Yang, H. (2022). A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects. Expert Opinion on Investigational Drugs, 31(7), 737-746.
● Scott, L. J. (2015). Lenvatinib: first global approval. Drugs, 75(5), 553-560.